EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RTP004 Peptide Binds to Botulinum Neurotoxin, Increases Cell Surface Binding, and Enhances Cellular SNAP-25 Cleavage

Andre F Batista, Ratnesh Singh, Frank Lee, Shaoqiu Zhuo, Dmitri Leonoudakis, Conor J Gallagher iD

Toxins · 10.03.2026 · 18 (3) · 134

DOI: 10.3390/toxins18030134 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxins, online erschienen am 10.03.2026. Verfasst von Andre F Batista und 5 weiteren Autor:innen. Beteiligte Einrichtung: Revance, 1222 Demonbreun St Suite 2000, Nashville, TN 37203, USA. Hauptthemen laut MEDLINE: Synaptosomal-Associated Protein 25, Botulinum Toxins, Type A, Peptides. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Revance Therapeutics, Revance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DaxibotulinumtoxinA for injection (DAXI) is a botulinum neurotoxin (BoNT) drug product comprising the 150 kDa pure BoNT/A1 as the drug substance formulated with a proprietary stabilizing excipient, RTP004. We hypothesized that RTP004 facilitates localization of BoNT/A1 to the neuronal membrane, resulting in increased BoNT internalization and cleavage of the synaptosomal-associated protein of 25 kDa (SNAP-25) within synaptic terminals. We characterized the interaction between RTP004 and BoNT/A1 using in silico and in vitro techniques. In vitro analyses revealed that negative charges on the BoNT/A1 surface were located on the light chain (LC, the catalytic domain) and the C-terminus of the heavy chain (HC, the receptor-binding domain), potentially providing sites for interaction with the positively charged RTP004 peptide. RTP004 bound to BoNT/A1, but not to human serum albumin (HSA), in both static and dynamic conditions. RTP004, not HSA, enhanced binding of BoNT to artificial membranes and RTP004 dissociated from BoNT under conditions that mimicked physiological conditions of the synaptic vesicle. RTP004 also increased binding of BoNT to the synaptosomal cell membrane and enhanced cleavage of SNAP-25 in a dose-dependent manner. These findings demonstrate that RTP004, not the excipient HSA common in other BoNT/A1 drug products, enhances binding of BoNT to the cell surface, facilitates internalization of BoNT into the cell, and increases SNAP-25 cleavage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Synaptosomal-Associated Protein 25Botulinum Toxins, Type APeptidesAnimalsHumansProtein BindingCell Membrane

Stichwörter der Autor:innen

RTP004SNAP-25botulinum neurotoxin type AdaxibotulinumtoxinAneuromodulatorpeptidesprotein transduction domain

Substanzen

Synaptosomal-Associated Protein 25Botulinum Toxins, Type APeptidesSnap25 protein, rat

Autor:innen und Institutionen

  • Revance, 1222 Demonbreun St Suite 2000, Nashville, TN 37203, USA.

ORCID-Profile: Conor J Gallagher

Förderung

  • Revance Therapeutics
  • Revance

Zitieren

APA

Batista, A. F., Singh, R., Lee, F., Zhuo, S., Leonoudakis, D., & Gallagher, C. J. (2026). RTP004 Peptide Binds to Botulinum Neurotoxin, Increases Cell Surface Binding, and Enhances Cellular SNAP-25 Cleavage. Toxins, 18(3), 134. https://doi.org/10.3390/toxins18030134

Vancouver

Batista AF, Singh R, Lee F, Zhuo S, Leonoudakis D, Gallagher CJ. RTP004 Peptide Binds to Botulinum Neurotoxin, Increases Cell Surface Binding, and Enhances Cellular SNAP-25 Cleavage. Toxins. 2026;18(3):134. doi:10.3390/toxins18030134

BibTeX
@article{Batista2026,
  author = {Batista, Andre F and Singh, Ratnesh and Lee, Frank and Zhuo, Shaoqiu and Leonoudakis, Dmitri and Gallagher, Conor J},
  title = {RTP004 Peptide Binds to Botulinum Neurotoxin, Increases Cell Surface Binding, and Enhances Cellular SNAP-25 Cleavage},
  journal = {Toxins},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {134},
  doi = {10.3390/toxins18030134}
}
Kostenlos starten →